Veterinary Medicines

FATROXIMIN endomammario asciutta 100 mg/5 ml pomata intramammaria per bovine e bufale

Authorised
  • Rifaximin
Download as PDF

Product identification

Medicine name:
FATROXIMIN endomammario asciutta 100 mg/5 ml pomata intramammaria per bovine e bufale
Active substance:
  • Rifaximin
Target species:
  • Cattle (cow)
  • Buffalo (female)
Route of administration:
  • Intramammary use

Product details

Active substance and strength:
  • Rifaximin
    100.00
    milligram(s)
    /
    1.00
    Syringe
Pharmaceutical form:
  • Intramammary emulsion
Withdrawal period by route of administration:
  • Intramammary use
    • Cattle (cow)
      • Milk
        0
        day
      • Meat and offal
        0
        day
    • Buffalo (female)
      • Milk
        0
        day
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ51XX01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Italy
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Fatro S.p.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Fatro S.p.A.
Responsible authority:
  • Ministry Of Health
Authorisation number:
  • 100077
Date of authorisation status change:

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Italian (PDF)
Published on: 12/12/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."